AbbVie strikes the Supreme Courtroom to assessment the bogus litigation

AbbVie Inc. has asked the US Supreme Court to review a federal appeals court ruling that it and its partner Besins Healthcare Inc. violated antitrust laws by filing a fake patent complaint over a generic version of its blockbuster testosterone replacement drug AndroGel delay.

In a petition filed Thursday for Certiorari, Seth P. Waxman of Wilmer Cutler Pickering Hale & Dorr, on behalf of the North Chicago, Illinois-based pharmaceutical company, argued that the U.S. 3rd Court of Appeals wrongly ruled that the complaint was fraudulent to show that it acted with bad faith. To read the full story on Westlaw Today, click here:

Comments are closed.